Strides Arcolab receives 2 NDA approvals from US-FDA

Strides Arcolab Ltd on March 14, 2007 has announced that it has received tentative approvals from the United States - Food and Drug Administration for two new drug applications (NDA) for fixed dose combination of:

- Lamivudine / Stavudine 150 mg / 40 mg Tablets and

- Lamivudine / Stavudine 150 / 40mg tablets Co-packaged with Nevirapine 200 mg Tablets.

both under the expedited review provisions of the President's Emergency Plan for Aids Relief (PEPFAR) program. This takes the total NDAs / ANDAs approvals received to 8 under the PEPFAR program.

Arun Kumar - Vice Chairman and Managing Director, of the Company said "the 2 new NDA approvals being key products in the treatment of HIV will provide a fillip to our Aids, TB and Malaria (ATM) initiative"

The Company also partners the Clinton Foundation to ensure availability of affordable quality generic ARVs in least developed countries.

Source : Equity Bulls

Keywords